INTRODUCTION
• Parkinson's disease (PD) is a well-known neurodegenerative disorder affecting people age >50 years. Prevalence of PD increases dramatically after the age of 60 years. 1 • Reviews have shown that the prevalence of PD in China was approximately 1.0%, which was lower than the PD prevalence reported in European countries. [1] [2] [3] [4] • However, China has the largest population in the world a n d the burden of PD is high when the prevalence rate is translated into total population living with PD.
• Health economics evidence of PD in China is poorly understood as English publications on PD in China are extremely limited. Thus, a structured literature review on cost of managing PD in China was performed.
• A structured literature review on published articles in both English and Mandarin languages were conducted. 
METHODOLOGY
• A total of 11 articles (10 Mandarin and 1 English) were included and reviewed. 3 articles by Wang et al. were reporting result from same study. The characteristics of 9 included studies are shown in Table 1 .
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• According to studies conducted in Shanghai and Nanjing, the total spending in managing PD increased with increase severity of PD as determined using Hoehn & Yahr (H&Y) score (Figure 1 & 2) . [12] [13] [14] Considering the close proximity between Shanghai and Nanjing, an indirect comparison between the 2 figures also showed increased cost of managing PD from year 2006 to 2012.
• The cost of managing PD in China differed between regions, types of prescribed treatment, as well as cost data definition; ranging from RMB 1,500 (USD 241) to RMB 13,000 (USD 2,100) for direct cost and RMB 100 (USD 16) to RMB 13,000 (USD 2,100) for indirect cost.
• Monotherapy with levodopa incurred higher indirect cost compared to combination therapy.
• The detailed breakdown of direct and indirect cost by region and by types of prescribed treatment is shown in Table 2 . • Combination treatment with DA was associated with higher direct costs compared to levodopa monotherapy; however combination therapy reduced indirect costs compared to levodopa monotherapy.
RESULTS
• Differences in cost results reported are most likely attributed to differences in study methodology, cost evolution over time and possible geographical variation. 
CONCLUSIONS

